Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders (2010 - 2026)

Jazz Pharmaceuticals' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 417.22% year-over-year to $293.1 million; the TTM figure through Mar 2026 stood at $29.7 million (down 93.85% YoY), while the FY2025 annual figure was -$355.4 million, down 163.27% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $293.1 million, up from $203.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $293.1 million in Q1 2026, with the low at -$718.4 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is $94.6 million (2023), against an average of $41.3 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 641.44% in 2022, then soared 1116.53% in 2023.
• Jazz Pharmaceuticals' Net Income towards Common Stockholders stood at -$240.0 million in 2022, then surged by 139.44% to $94.6 million in 2023, then jumped by 102.0% to $191.1 million in 2024, then advanced by 6.47% to $203.5 million in 2025, then soared by 44.02% to $293.1 million in 2026.
• Business Quant data shows JAZZ's Net Income towards Common Stockholders at $293.1 million in Q1 2026, $203.5 million in Q4 2025, and $251.4 million in Q3 2025.